On June 8, Kelun-Biotech fell 3.15% in regular trading, trading at HKD 381.2 per share, with trading volume of HKD 55.83 million.

On the news front, the decline is attributed to continued selling pressure from the chairman's recent share disposals combined with the company's widening losses. Hong Kong Exchange filings revealed that Chairman Liu Gexin sold approximately 257,300 shares across three consecutive trading days from May 26 to May 28, further intensifying market concerns about insider confidence.

On the fundamentals side, the company's latest earnings showed revenue growth of 6.5% to RMB 2.058 billion, but net losses expanded to RMB 382 million, primarily dragged by a significant decline in authorization and milestone income alongside elevated R&D expenses. Although the company recently announced a share buyback authorization plan for up to 10% of issued H shares and received strong clinical data support at the ASCO annual meeting, the chairman's sustained selling signal continues to suppress short-term market sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)